Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021
Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the virtual Improvate Life-Saving Technologies International Conference 2021 being held on Thursday, July 22, 2021. During the interview, which will take place at approximately 5:15 AM EDT (12:15 PM Israel time), Dr. Hershkovitz will discuss the Company’s AllocetraTM macrophage reprogramming cell therapy platform, which is being developed for life-threatening unmet medical conditions, and the Company’s current development plans.
The live broadcast can be accessed by registering through the conference’s website at https://improvate.net/life_saving_technologies_2021/.
ABOUT IMPROVATE AND THE LIFE-SAVING TECHNOLOGIES INTERNATIONAL CONFERENCE 2021
IMPROVATE is a platform that makes technology and innovation accessible to countries around the world, with an emphasis on advancing Israeli technologies. Launched in September 2020, IMPROVATE operates out of London and Tel Aviv and serves as a platform to connect leaders, decision makers, companies, and investors with technology and innovation companies. IMPROVATE works through international conferences and business delegations and promotes deals between governments, organizations and investors with technology and innovation companies. Among IMPROVATE’s Board members are former world chess champion Garry Kasparov, former Bulgarian President Rosen Plevneliev (2010-2017), and IDF Major Gen. (Ret.) Amos Gilad. The Improvate Life-Saving Technologies International Conference 2021 will be attended by health and science ministers from several countries in Europe, and will focus on potentially life-saving technologies.
AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.
Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
INVESTOR RELATIONS CONTACT
View source version on GlobeNewswire.com